


iShares

# iShares Nasdaq US Biotechnology ETF Dis

IE00BDZVHG35

19-05-2026

FM



## Investment objective

The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index. The Index measures the performance of companies listed on the NASDAQ Stock Market that are classified as either biotechnology companies or pharmaceutical companies, according to their Industry Classification Benchmark (ICB) and that also meet other eligibility criteria as determined by NASDAQ, Inc. (the Index Provider), including minimum market capitalisation and liquidity requirements.

## Fees

Entry fee	-->Tarievenkaart / Cost information sheet
Exit charges	-->Tarievenkaart / Cost information sheet
Estimated ongoing charges	0,35%

## Quote

Quote	\$8,28
Quote date	18-05-2026

## Performance in EUR

Date	18-05-2026
This year	1,17%
1 week	-2,40%
1 month	-5,29%
3 months	-3,09%
6 months	1,57%
1 year	35,00%
3 years (annualised)	8,84%
5 years (annualised)	5,28%
Since start (annualised)	7,28%

## Dividend

Dividend paying	Yes
Dividend	\$0,01
Ex-dividend date	11-12-2025
Payment date	24-12-2025
Dividend frequency	Semi-Annually

## Indicators

Standard deviation (3yr)	16,00%
Share ratio (3yr)	0,50
Beta (3yr)	0,81
Alpha (3yr)	7,34
Tracking error (3yr)	10,30


## Top 10 holdings (30-04-2026)

Amgen Inc	7,39 %
Gilead Sciences Inc	7,28 %
Vertex Pharmaceuticals Inc	7,13 %
Regeneron Pharmaceuticals Inc	5,92 %
Anylam Pharmaceuticals Inc	3,31 %
Insmid Inc	2,37 %
Revolution Medicines Inc Ordinary Shares	2,30 %
Biogen Inc	2,24 %
United Therapeutics Corp	2,02 %
argenx SE ADR	1,78 %

?>

## Characteristic

Asset Manager	iShares
Asset class	Equities
Investment category	Equities - Healthcare
Active/Passive	Passive
Fund code	290133
Fund code fractional orders	-
Fund manager name	Not available
ISIN	IE00BDZVHG35
Sustainable Classification	-
Sustainability Rating	
Domicile	Ireland
Currency	USD
Fund size (mio)	\$735,17 (18-05-2026)
Cut-off time	-
Execution date	niet van toepassing: directe verhandeling op de beurs
Inception date	05-03-2018
Benchmark	NASDAQ Biotechnology TR USD
Minimum investment amount	-
Assortiment	Self Directed Investing Plus, Investment advice



- United Kingdom
- Australasia
- Developed Markets Asia
- Emerging Markets Asia
- North America
- Developed Markets Europe
- Africa & Middle East

**General Disclaimer**

The information provided in this document has been drafted by ABN AMRO Bank N.V

**About ABN AMRO**

ABN AMRO Bank N.V. has its registered office at Gustav Mahlerlaan 10, 1082 PP Amsterdam (the Netherlands). Telephone: 0900 - 0024\*. Internet: abnamro.nl ABN AMRO Bank N.V. holds a banking licence from De Nederlandsche Bank N.V. (the Dutch central bank) and is included in the register of the Autoriteit Financiële Markten (AFM - Authority for the Financial Markets) under number 12000004. ABN AMRO Bank N.V. is entered in the Trade Register of the Amsterdam Chamber of Commerce under number 34334259. The VAT identification number of ABN AMRO Bank N.V. is NL8206.46.660B01.

**US Securities Law Disclaimer**

ABN AMRO Bank N.V. ('ABN AMRO') is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the '1934 Act') and under applicable state laws in the United States. In addition, ABN AMRO is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the 'Advisers Act' and together with the 1934 Act, the 'Acts'), and under applicable state laws in the United States. Accordingly, absent specific exemption under the Acts, any brokerage and investment advisory services provided by ABN AMRO, including (without limitation) the investment products and investment services described herein are not intended for U.S. persons. Neither this document, nor any copy thereof may be sent to or taken into the United States or distributed in the United States or to a US person. Without limiting the generality of the foregoing, the offering, sale and/or distribution of the investment products or investment services described herein is not intended in any jurisdiction to any person to whom it is unlawful to make such an offer, sale and/or distribution. Persons into whose possession this document or any copy thereof may come, must inform themselves about, and observe, any legal restrictions on the distribution of this document and the offering, sale and/or distribution of the investment products and investment services described herein. ABN AMRO cannot be held responsible for any damages or losses that occur from transactions and/or services in defiance with the restrictions aforementioned.

\* Call charges: for this call you pay your usual call charges set by your telephone provider